CAS: 35349-68-9; 5,9-Dihydroxy-8-Methoxy-2,2-Dimethyl-7-(3-Methylbut-2-En-1-yl)Pyrano[3,2-B]Xanthen-6(2H)-One
该化合物是属于Xanthone类的化学化合物,其特点是三环结构,含有一种中苯丙酮混合物,该化合物通常呈现黄色至橙色,这是xanthones之间常见的特征,因为其结合的双重结合系统. Xanthone I以其潜在的生物活动,包括抗氧化剂,抗炎和抗微生物特性而著称,这使其在药物和营养研究中引起兴趣.其溶解性因溶剂而异,在紫外光下可能表现出荧光,这是许多苯丙酮的一个特征.该化合物的稳定性和再活动可能受附于Xanthone核心的功能组的存在的影响.
- 英文名称5,9-Dihydroxy-8-Methoxy-2,2-Dimethyl-7-(3-Methylbut-2-En-1-yl)Pyrano[3,2-B]Xanthen-6(2H)-One
- 中文名称氧杂蒽酮 I
- IUPAC名称5,9-dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-2H,6H-pyrano[3,2-b]xanthen-6-one
- 其它别名9-Hydroxycalabaxanthone; Hydroxycalabaxanthone, 9-; 1,6-Dihydroxy-7-Methoxy-8-(3-Methylbut-2-Enyl)-6',6'-Dimethylpyrano(2',3':3,2)Xanthone; Xanthone I; 5,9-Dihydroxy-8-Methoxy-2,2-Dimethyl-7-(3-Methyl-2-Buten-1-yl)-2H,6H-Pyrano[3,2-B]Xanthen-6-One; 2H,6H-Pyrano[3,2-B]Xanthen-6-One, 5,9-Dihydroxy-8-Methoxy-2,2-Dimethyl-7-(3-Methyl-2-Buten-1-yl)-; 5,9-Dihydroxy-8-Methoxy-2,2-Dimethyl-7-(3-Methylbut-2-Enyl)Pyrano[3,2-B]Xanthen-6-One; 5,9-Dihydroxy-8-Methoxy-2,2-Dimethyl-7-(3-Methylbut-2-En-1-yl)Pyrano[3,2-B]Xanthen-6(2H)-One
- CAS编号35349-68-9
- MFCD编号:MFCD09264656
- 分子式:C24H24O6分子量:408.45
- 产品CID: 1360878
- 产品分类天然产物 → 氧杂蒽酮
物理性质
MSDS等安全信息
上下游产品
CAS号6147-11-1 α-倒捻子素合成工艺路线路线简述
📜α-倒捻子素置于2,3-二氯-5,6-二氰基-1,4-苯醌体系中,用 苯 用作溶剂,以63 %的收率获得氧杂蒽酮 I
参考文献:新型氧杂蒽酮类抗菌剂:半合成,生物学评价和作用机制
标题:新型氧杂蒽酮类抗菌剂:半合成,生物学评价和作用机制
摘要:α-Mangostin (α-Mg) 已证明对革兰氏阳性细菌显示出有效的活性.然而,α-Mg 的酚羟基对抗菌活性的贡献仍然不清楚,严重阻碍了结构修饰的选择以开发更多潜在的基于 α-Mg 的抗菌衍生物.在此,设计,合成并评估了 21 种 α-Mg 衍生物的抗菌活性.结构活性关系(sars)显示酚基的贡献顺序为c3>C6>C1,C3处的酚羟基对抗菌活性至关重要.值得注意的是,与母体化合物 α-Mg 相比,10A由于其更高的选择性和不溶血,以及在动物皮肤脓肿模型中更有效的抗菌功效,在 C1 处具有一个乙酰基的化合物表现出更高的安全性.我们的证据进一步表明,与 α-Mg 相比,10A具有更强的膜电位去极化能力,并导致更多的细菌蛋白泄漏,这与透射电子显微镜 (Tem) 观测到的结果一致.转录组学分析表明,这些观察结果可能与参与膜通透性和完整性生物过程的蛋白质合成受到干扰有关.总的来说,我们的研究结果为开发基于
Doi:10.1016/j.Bmc.2023.117232
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2902500000-苯乙烯
2902600000-乙苯 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1. Liang, J., Huang, Y.-Y., Zhou, Q., et al. Discovery and optimization of α-mangostin derivatives as novel PDE4 inhibitors for the treatment of vascular dementia. J. Med. Chem. 63(6), 3370-3380 (2020). 2. Han, A.-R., Kim, J.-A., Lantvit, D.D., et al. Cytotoxic xanthone constituents of the stem bark of Garcinia mangostana (mangosteen). J. Nat. Prod. 72(11), 2028-2031 (2009). 3. Munar-Bestard, M., Rodríguez-Fernández, A., Ramis, J.M., et al. In vitro evaluation of mangostanin as an antimicrobial and biocompatible topical antiseptic for skin and oral tissues. ACS Pharmacol. Transl. Sci. 7(5), 1507-1517 (2024). 4. Chaijaroenkul, W., and Na-Bangchang, K. The in vitro antimalarial interaction of 9-hydroxycalabaxanthone and α-mangostin with mefloquine/artesunate. Acta Parasitol. 60(1), 105-111 (2014). 5. Abate, M., Pagano, C., Masullo, M., et al. Mangostanin, a xanthone derived from Garcinia mangostana fruit, exerts protective and reparative effects on oxidative damage in human keratinocytes. Pharmaceuticals (Basel) 15(1), 84 (2022)合成参考文献
参考文献:10.1016/s0031-9422(96)00410-4
摘要:Chairungsrilerd N, Takeuchi K, Ohizumi Y, Nozoe S, Ohta T. Mangostanol, a prenyl xanthone from Garcinia mangostana. Phytochemistry. 1996 Nov;43(5):1099–102. doi: 10.1016/s0031-9422(96)00410-4.
参考文献:10.1016/s0031-9422(00)82235-9
摘要:K. Sen A, K. Sarkar K, C. Mazumder P, Banerji N, Uusvuori R, A. Haset T. A xanthone from Garcinia mangostana. Phytochemistry. 1980 Jan;19(10):2223–5. doi: 10.1016/s0031-9422(00)82235-9.
参考文献:10.1007/978-94-007-1764-0_15
摘要:Lim TK. Garcinia mangostana. 2011 Nov 06. In: Edible Medicinal And Non-Medicinal Plants.
参考文献:10.1016/j.bmc.2010.07.033
摘要:Ryu HW, Curtis-Long MJ, Jung S, Jin YM, Cho JK, Ryu YB, Lee WS, Park KH. Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 01;18(17):6258–64. doi: 10.1016/j.bmc.2010.07.033.
参考文献:10.1021/acs.jmedchem.1c01085
摘要:Huang YY, Deng J, Tian YJ, Liang J, Xie X, Huang Y, Zhu J, Zhu Z, Zhou Q, He X, Luo HB. Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety. J Med Chem. 2021 Sep 23;64(18):13736–51. doi: 10.1021/acs.jmedchem.1c01085.
📝 需求与反馈
尽可能描述清楚需求与问题信息
